Comprehensive perspectives on critical issues
Thomson Reuters Recap publishes periodic reports on key issues related to biopharma partnership and licensing issues. By taking advantage of our database of deals, our analysts explore a variety of market segments and trends from every available perspective in order to glean the critical insights that power smarter decisions. Browse our reports below.
THE RECAP OF 2015 DEALMAKERS REPORT
Effectively benchmark your proposed deals for 2016 and beyond. The 2015 Dealmakers Report is a comprehensive, in-depth analysis of 2015's key life sciences deals trends. Identify changes in the dealmaking space impacting you, compare your proposed deal structures against the top relevant deals from last year, and quickly identify opportunities to strengthen your strategy.
Benefit from our expert analyses of the 2015 dealmaking climate. Implement your own analyses on nearly the 4000 publicly announced deals in 2015, 1300 of which had disclosed an aggregate value of $700 billion. Gain deeper insights into the licensing landscape and M&A trends, and make confident decisions on where to direct your deal making attention for 2016 and beyond.
The report includes:
- A 34-page PowerPoint deck prepared by our expert deals analysts, regarding the key dealmaking trends of 2015
- Data on all 4000 announced 2015 deals in a 48-column Excel spreadsheet, for your own internal analyses
- A packet of BioWorld Today reprints on more than 20 top bio/pharma transactions announced in 2015, to increase your in-depth understanding of these industry-leading transactions
- A 20-slide PowerPoint deck of the famous Recap Snapshots for the largest 10 M&A transactions and largest 10 licensing deals of 2015, for quick overviews of the key components of these headline deals
Whether you're buying or selling, the 2015 Dealmakers Report gives you insights to make the best deals for all parties, based on trusted and accurate data and assessments.
Recap Therapeutic Area Insights
Oncology Deal Making & Development Trends, 2008-2012
- From 2008-2012, Phase II oncology assets earned a median upfront fee of $31.5 million for sellers, a 142% jump from Phase I and the highest step-up at any stage.
- Overall, oncology licensing activity between 2008-2012 shows a dominant and sustained focus on early stage (Discovery through Phase I) assets: About 70% of deals in each of the five years were for early stage assets.
- Oncology M&A trends mirror the focus on early stage assets: 30% of oncology target companies had pre-Phase II development stage products versus just 15% of non-oncology targets.
- The median announced deal size for oncology licenses and joint ventures from 2008-2012 was $334 million (average: $417 million), which ranked it as the second highest therapeutic area in terms of deal size after Autoimmune/Inflammatory (median: $405 million, average: $492 million).